Central Nervous System Lymphoma clinical trials

Explore recruiting central nervous system lymphoma clinical trials.

Recruiting central nervous system lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Central Nervous System Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants with Relapsed/Refractory Primary Central Nervous System Lymphoma

Czechia, Germany, Italy, Belgium, Spain, Poland +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients

France, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Chemoimmunotherapy in conjunction with blood-brain-barrier opening in patients with newly diagnosed or relapsed primary central nervous system lymphoma

Finland

Therapeutic exploratory (Phase II) EU CTIS Study details

Evaluation of the safety and efficacy of Berubicin in the treatment of central nervous system lymphomas- BERUBICIN

Poland

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction treatment for patients aged 18 to 60 (up to 65 for phase II) with a newly diagnosed Primary Central Nervous System Lymphoma

France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

HOVON 176: Golcadomide (CC-99282) for relapsed and refractory primary large B-cell lymphoma of the central nervous system and secondary central nervous system lymphoma: a phase 2 study

Netherlands, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Central Nervous System Lymphoma trials by city

Central Nervous System Lymphoma in Toronto Central Nervous System Lymphoma in Vancouver Central Nervous System Lymphoma in Montreal Central Nervous System Lymphoma in Calgary Central Nervous System Lymphoma in Edmonton Central Nervous System Lymphoma in Ottawa Central Nervous System Lymphoma in Winnipeg Central Nervous System Lymphoma in Quebec City Central Nervous System Lymphoma in Hamilton Central Nervous System Lymphoma in Kitchener Central Nervous System Lymphoma in London Central Nervous System Lymphoma in Halifax Central Nervous System Lymphoma in New York Central Nervous System Lymphoma in Los Angeles Central Nervous System Lymphoma in Chicago Central Nervous System Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease